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Disseminated candidiasis, especially ocular infections such as endophthalmitis, is uncommon in HIV-infected
patients. We report a case of candidal endophthalmitis in an HIV-positive non-drug-user patient,
following candidemia from a cutaneous abscess at the site of a peripheral catheter. Ocular disease was revealed
by a visual decrease in the left eye. DNA analysis using RAPD showed identical patterns of Candida albicans
isolated from the skin and eye. Combination therapy with high-dose fluconazole and intravenous
amphotericin B was performed. Two intravitreal amphotericin B injections and a vitrectomy were
administered because of an amblyopic right eye and severe vitritis. The outcome was favorable without
relapse at 18 months.
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CASE REPORT
A 31-year-old heterosexual man, found to be positive for HIV
in November 1996, was admitted in February 1997 after a 1-day
history of sudden blurred vision in the left eye. He was admitted
to hospital for the first time in November 1996 with a 1-month
history of fever (38–38.5 8C), a cough, a 5-kg weight loss, and
sweating at night. Bacterial sinusitis and pneumonia caused by
Streptococcus pneumoniae and Haemophilus influenzae were diag-
nosed. Both isolates were susceptible to amoxicillin. A severe
HIV-related immunocompromised state was subsequently
established (CD4 cell count, 11/mm3; HIV-1 viral load,
6.1 log10). He initially improved with intravenous amoxicillin
(6 g daily) and was considered cured after 15 days of treatment.
Three days later his fever relapsed (39 8C). Blood and maxillary
sinus culture yielded S. pneumoniae, with an antibiotype similar
to the first one. Pseudomonas aeruginosa was also found in the
sinus. Despite prolonged intravenous therapy with vancomycin,
ceftazidime and ciprofloxacin, fever persisted for 15 days.
During this period, various abnormalities appeared, such as
prolonged pancytopenia (>15 days) with severe neutropenia
(neutrophil count,<100/mm3) and thrombocytopenia (platelet
count, 11 000/mm3) associated with cytolysis, hyperferritine-
mia and hypertriglyceridemia. No opportunistic infection or
tumor-associated event was found. Two bone-marrow punc-
tures revealed dysmyelopoiesis with hemophagocytosis. A low
dose of fluconazole (50 mg daily) was administered for 5 days
only to cure oral candidiasis and was stopped abruptly because
of severe cytolysis. However, two cultures of stool and one of
sputum revealed numerous Candida albicans isolates. On 14
January 1997, a combination of lamivudine, stavudine and
indinavir was initiated. On 18 January, fever and hematologic
abnormalities resolved (white blood cells 3100/mm3; neutro-
phils 2200/mm3; hemoglobin 9.6 g/dL, and platelets 155 000/
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mm3). On clinical examination, a cutaneous abscess was found
at a peripheral infusion site. The abscess was drained, and
microbiogical investigation revealed C. albicans. The patient
left hospital the same day on fluconazole treatment of 100 mg/
day, which was not supervised. During the next 10 days, he
experienced episodes of fever before discovering sudden
blurred vision in the left eye.
By admission on 3 February 1997, visual acuity was reduced
to 20/60 for the left eye (previous visual acuity, 20/25) while
the right eye was deeply amblyopic (visual acuity reduced to
counting fingers in relation to a unilateral high myopia). Slit
lamp examination did not reveal any inflammation in the right
eye, but revealed an inflammatory process in the left eye. There
was slight flare, and cells in the anterior chamber. Fundus
examination disclosed a creamy-white chorioretinal lesion,
1/2 disk diameter in size, located inferior and temporal to
the optic disk. There was vitreous inflammation overlaying
the chorioretinitis with strand-like clusters of inflammatory
cells and diffuse cellular infiltration (grade 3þ, see Figure 1).
Ophthalmologic examination was consistent with a candida
endophthalmitis. Fluconazole therapy was increased (800 mg/
day for 2 days, then 400 mg daily) and an intravitreal injection of
amphotericin B was given the following day (0.5 mg/0.1 mL) in
order to act directly and quickly at the site of infection and to
avoid the C. albicans strain becoming resistant to fluconazole. In
addition, intravenous amphotericin B (0.5 mg/kg/day) was
administered on day 5. No other site of candida infection
(heart, kidney, skin) was identified, and cultures of urine, blood
and stools were sterile.
Despite these measures, no clear improvement of the vitreous
and retina was noted on day 8. The patient underwent a
vitrectomy on day 10, followed by a second intravitreal injection
of amphotericin B immediately after surgery. A culture of
vitreous humor yielded C. albicans. Two assays for candidal
antigenemia (Latx test, Pastorex, Candida-Pasteur) were nega-
tive. Specific antibodies were detected at 1/640 by hemagglu-
tination test (Fumouze) and 1/800 by immunofluorescence
assay (Biomerieux). Finally, the patient received 7 weeks of
an antifungal combination. Intravenous amphotericin B was
stopped (total dose 1200 mg) when fundoscopic examination
confirmed that chorioretinitis was completely resolved and
when susceptibility of the yeast to fluconazole was shown
(MIC¼ 0.50 mg/L by broth microdilution method). Oral flu-
conazole monotherapy was given for 1 additional month. The
total duration of fluconazole therapy was 80 days (total dose,
32 800 mg). Eighteen months after the onset of the candida
chorioretinitis, no relapse occurred and left visual acuity
remained at 20/30 (Figure 2). In order to genotype both C.
albicans isolates, random amplified polymorphic DNA analysis
(RAPD) was performed.
Genomic DNA extraction was performed as described [1].
The primers used were R4 (50-TGGTCGCGGC-30) [1] and a
combination of C1 (50-ACGGTACACT-30) and C3 (50-
GTTTCCGCCC-30) [2]. The RAPD fingerprinting was per-
formed as previously described [2] with some modifications.
The PCR mixture consisted of a buffer (10 mM Tris-HCL
pH 8.3, 50 mM KCL, 2.5 mM MgCl2, 0.01% (w/v) gelatine),
400 mM each of the four desoxynucleotide triphosphates
(Amersham Pharmacia Biotech, Orsay, France), 50 pmol of
primer, 200 ng of genomic DNA, and 2 U of Taq DNA
polymerase (Perkin, Les Ulis, France), in a total volume of
50 mL. DNA was amplified with a Perkin-Elmer thermal cycler
Figure 1 Candidal chorioretinitis located temporal and inferior to the optic
disk. Late staining on fluorescein angiography.
Figure 2 Same lesion as in Figure1, following vitrectomy and medical
treatment.
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9600 as follows: 94 8C for 5 min, then 40 cycles consisting of
94 8C for 1 min, 36 8C for 1.5 min, and 72 min for 3 min,
followed by a final extension step at 72 8C for 10 min. Amplified
products were separated by electrophoresis in a 1.5% agarose gel
(Life Technologies, Eragny, France) and visualized by UV
transillumination following ethidium bromide staining. A 1-kb
DNA ladder (Life Technologies) was used as a molecular
size standard. The fingerprints were compared visually, and
patterns were considered different when at least one major or
two minor amplification bands differed, regardless of band
intensity [3].
The RAPD fingerprint profiles obtained with primers C1/
C3 and with primer C4 of the two C. albicans isolates are shown
in Figures 3a and 3b, respectively. The banding patterns of
these two isolates were highly conserved but different from
that of an unrelated C. albicans strain. The RAPD results showed
that the profiles obtained for the two C. albicans isolates
were indistinguishable, suggesting a genetic identity between
them.
DISCUSSION
Invasive candidiasis, especially ocular infections such as
endophthalmitis, are unusual in AIDS [4,5]. In these immu-
nocompromised patients, candida endophthalmitis is mostly
reported in cases of intravenous drug abuse and is often
associated with a brown heroin syndrome [6,7]. In contrast,
our case occurred in a severely immunosuppressed heterosexual
man with no drug history. His candida endophthalmitis was
revealed by sudden blurred vision of the left eye without
metastatic locations [6,7]. Cytomegalovirus retinitis was ruled
out. The diagnosis of candida endophthalmitis was quickly
considered and treated because of fever, history of a recent
candida cutaneous abscess and findings of the ophthalmologic
examination. According to our observations, risk factors for the
development of disseminated candidiasis were broad-spectrum
antibiotic treatment, prolonged and profound neutropenia,
colonization by C. albicans of sputum and stool, and previous
cutaneous candida abscess. As deficiency of the cell-mediated
immune response caused by HIV is not a risk factor for invasive
candidiasis, candida endophthalmitis is infrequent in AIDS
patients [4,8]. In contrast, a severe and prolonged neutropenia,
as in our case, is a major factor in fungal infections [4,8].
Hematologic abnormalities (pancytopenia due to dysmyelopoi-
esis with hemaphagocytosis) were possibly related to HIV, as
they rapidly improved with antiretroviral therapy. Moreover, as
in neutropenic patients, candida infection was unmasked when
neutropenia disappeared. Conversely, in this case, antiretroviral
therapy slowly enhanced immune function with a CD4 cell
count of 28/mm3 after 6 weeks, but with a good virologic
response at the same time (HIV viral load¼ 2.4 log10).
At the onset of endophthalmitis, the restitution of immune
function on antiretroviral therapy was poor, which is in-
consistent with a major role of cellular immunity in this invasive
candidiasis as previously reported for CMV and cryptococ-
cal infections [9,10]. Moreover, invasive candidiasis is not
Figure 3 RAPD profiles of both C. albicans clinical isolates (on a1.5% agarose gel) obtained with (a) a combination of primers C1and C3 and (b)with primer
R4. Lanes1and 2 represent the profiles ofC. albicans isolates from the cutaneous abscess and vitreous humor, respectively. Lane Ucorresponds to the profile
of anunrelatedC. albicans strain. LaneMrepresents themolecular weight marker1-kbTM (LifeTechnologies); some sizes are indicated on the right-hand side of
the gel (in kb).
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dependent on cell-mediated immunity, like CMV or crypto-
coccal infection, but depends on neutrophil cells.
Although endogenous endophthalmitis follows candidemia,
blood cultures are often negative, as noted in our report [6].
However, RAPD analysis provided some evidence for the
hematogenous spread of C. albicans in demonstrating identical
profiles for both ocular and cutaneous isolates.
Although the ideal therapy for candida endophthalmitis has
not been defined, amphotericin B remains the standard drug
recommended [11]. However, its penetration into the eye and
particularly into the vitreous is limited, and this may explain a
number of therapeutic failures [12,13]. Moreover, amphoter-
icin B is nephrotoxic, and its use requires intravenous admin-
istration monitored in hospital. Conversely, animal studies in
the rabbit have shown that fluconazole, a triazole antifungal
agent, can display good penetration into both an inflamed and
uninflamed choroid and vitreous body after either intravenous
or oral administration [14,15]. Two recent prospective rando-
mized trials compared amphotericin B (0.5–0.67 mg/kg daily)
with fluconazole (400 mg daily) as treatment for candidemia
[16,17]. The first study was carried out in 206 patients without
neutropenia (neutrophil count >500/mm3), and the second in
142, among who one-third were neutropenic. Both studies
suggested that fluconazole was as effective as and less toxic than
amphotericin B in the treatment of invasive candida infections.
However, these studies did not include HIV-infected patients,
and only Rex et al. [16] analyzed the response in cases of
endophthalmitis. Among 29 candida endophthalmitis cases (13
in the amphotericin B group and 16 in the fluconazole group),
only one initially treated with fluconazole required both intra-
venous amphotericin B and vitrectomy in order to be cured.
Alker et al. [5] retrospectively described six patients with
candida endophthalmitis treated with fluconazole and reviewed
21 other cases from the literature. Fluconazole was used as the
sole therapy for 14 patients with 16 infected eyes. Endophthal-
mitis was cured with fluconazole alone in 15 (94%) of 16 eyes,
including five with vitritis. Successful treatment required the
administration of fluconazole (100–200 mg PO daily) for an
average duration of 65 days (range 19–138).
CONCLUSIONS
Our report emphasizes the difficulty of candida endophthalmitis
treatment. It is significant that a C. albicans strain was still isolated
at day 10 of a multiple therapy regimen (10 days of fluconazole,
400 mg daily, 5 days of intravenous amphotericin B, and one
intravitreal amphotericin B injection). The fungistatic activity
of both fluconazole and amphotericin B might explain the slow
clearance and sterilization of the yeasts from the eye. Flucytosine
is another antifungal agent that may be useful in combination
with amphotericin B. However, prolonged and high-dose
fluconazole therapy (200 mg daily for 2 months) seemed to
be as effective as the standard treatment with intravenous
amphotericin B as recommended in patients with chorioreti-
nitis alone [5,18]. According to previous studies, our case report
highlights the fact that vitrectomy with concurrent intravitreal
amphotericin B injection is probably useful to improve visual
prognosis for patients with moderate to severe vitritis, especially
when fluconazole alone is not rapidly effective [7,11,19].
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Fungemia due to Scedosporium prolificans: a description of two cases
with fatal outcome
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Two cases, probably related, of fungemia due to Scedosporium prolificans are described in two patients with acute
leukemia. Both were admitted to the hematological ward in nearby rooms, during building work
in the hospital. After a previous bacterial sepsis in the neutropenic phase, which improved with antibiotic
treatment, the respiratory status in both patients deteriorated presenting acute dypsnea, with a lung infiltrate
in one of them. A few hours later both patients died. Blood cultures were positive for S. prolificans.
These two new cases of S. prolificans infection stress the importance of awareness of this emerging pathogen in
patients who suffer a hematologic malignancy during the neutropenic phase, especially if building
work is taking place in the hospital.
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In the last two decades, the use of aggressive treatment and
techniques such as transplants, chemotherapy, catheter implants
and others to prolong the lives of patients, and the existence of
HIV, have created a new group of patients who are especially
susceptible to fungal infections, and consequently the morbidity
and mortality due to these organisms have witnessed notable
increases.
In 1984, Malloch and Salkin described the first case of human
infection due to Scedosporium inflatum [1]. Recent DNA analyses
have demonstrated that this fungus is identical to Lomentospora
prolificans, a species isolated in Belgium by Hennebert and Desai
[2], and, according to the current rules of botanical nomen-
clature, it was renamed Scedosporium prolificans. The natural
habitat of this fungus is not well known; it has been isolated
in soil from flower pots and also from cats and horses [3,4]. In
humans, the clinical spectrum of S. prolificans ranges from
asymptomatic colonisation to severe disseminated infections.
Most of these latter cases have been associated with immuno-
compromised patients, especially those with profound neutro-
penia. Contaminated air-conditioning systems and renovation
inside hospitals have been related to nosocomial infections
produced by several opportunistic fungi such as Aspergillus
spp. [5]; a report has recently been published on the first possible
outbreak of nosocomial infection due to S. prolificans [6].
Our study describes two new cases of fatal S. prolificans
infection in two leukemic patients coinciding with rebuilding
work in the hospital.
PATIENTS AND METHODS
Two leukemic patients had fungemia due to S. prolificans during
profound neutropenia. Both cases were detected in the same
ward over a period of 20 days and coincided with reconstruction
work at the hospital. Blood samples were inoculated into
aerobic and anaerobic bottles (Bactec Plus/F aerobic and
anaerobic; Becton Dickinson, Spacks, MD, USA) and processed
in the Bactec 9120 automatic system for 7 days. The bottles
were subcultured on blood agar and Sabouraud dextrose agar
(Difco, Detroit, MI, USA) when the system detected growth.
Environmental samples were taken from each of the rooms to
identify the reservoir. Saline-moistened sterile cotton swabs
were used for collecting samples from walls, floors, the surfaces
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